Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 21, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	122	130	69	38	118	49
Market Cap Growth	-36.87%	87.08%	83.20%	-68.02%	143.46%	5.47%
Enterprise Value	101	115	82	26	141	89
Last Close Price	1.66	1.78	1.37	0.83	3.63	3.28
PE Ratio	-	15.62	-	-	-	-
Forward PE	3.48	-	60.89	-	-	-
PS Ratio	2.66	1.98	1.46	0.99	1.88	0.89
PB Ratio	3.77	3.87	-6.52	-6.28	-4.38	-0.69
P/TBV Ratio	2.31	3.87	-	-	-	-
EV/Sales Ratio	2.20	1.75	1.72	0.68	2.24	1.62
EV/EBITDA Ratio	-	9.86	-	-	35.08	-
EV/EBIT Ratio	-	10.98	-	-	51.93	-
Debt / Equity Ratio	0.18	0.78	-3.15	-5.55	-2.38	-0.87
Debt / EBITDA Ratio	-	2.00	-	-	11.94	-
Asset Turnover	0.61	0.93	0.74	0.54	1.11	1.03
Inventory Turnover	1.51	1.28	1.13	1.05	1.02	1.30
Quick Ratio	1.22	1.11	0.84	1.29	0.48	0.58
Current Ratio	1.98	1.54	1.38	1.86	0.64	0.81
Return on Equity (ROE)	-27.18%	72.50%	-	-	-	-
Return on Assets (ROA)	-7.47%	9.32%	-12.57%	-18.06%	2.99%	-12.58%
Return on Capital (ROIC)	-10.88%	15.81%	-32.36%	-39.47%	12.11%	-
Earnings Yield	-7.86%	6.40%	-21.50%	-72.80%	-5.50%	-37.55%
FCF Yield	5.87%	-1.90%	-36.92%	-31.00%	-22.58%	-41.06%
Buyback Yield / Dilution	0.59%	-70.04%	-9.81%	-51.43%	-96.44%	-0.85%
Total Shareholder Return	0.59%	-70.04%	-9.81%	-51.43%	-96.44%	-0.85%

Source: S&P Capital IQ. Standard template. Financial Sources.